135 Results

UC researchers to study drug’s effects on COVID-19 patients

September 22, 2020

Researchers at the University of Cincinnati and UC Health will host a Phase 2 clinical trial (NCT04511650) to examine the effects of a drug that targets blood vessel inflammation and injury in patients with COVID-19. They will study the effects of razuprotafib, an investigational drug that activates a key pathway for stabilizing blood vessels in the lung and other organs in patients with moderate to severe cases of the respiratory illness caused by the novel coronavirus SARS-CoV-2. The drug may prevent and treat respiratory distress in COVID-19 patients. The Phase 2 clinical trial will assess safety, tolerability and efficacy of razuprotafib.

Yahoo News: Five Black UC faculty members receive National...

September 8, 2020

Five African-American researchers and healthcare professionals on UC’s medical campus have received sizable grants from the National Institutes of Health during the past 18 months. The faculty members were interviewed by WCPO to help showcase innovation and the diverse voices and perspectives they bring as the healthcare community attempts to ease health disparities in communities of color in Cincinnati and beyond.

Load More
Debug Query for this